NCT06889493 trial: what clinicians have said so far
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
- NCT06889493 ↗
- Recruiting
- Peter Hosein, MD
- Focused size, estimated: 1–150 verified statements once built
Discussed at: 2026 ASCO Annual Meeting, ESMO Congress 2026
We haven't built an HCP commentary report on NCT06889493 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06889493 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Trial of the Oncolytic Virus SVV-001 in Combination With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas or Well-Differentiated High-Grade (Grade 3) Neuroendocrine Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Neuroendocrine Carcinoma; Neuroendocrine Tumors
- Interventions
- Seneca Valley Virus-001 (SVV-001); Nivolumab; Ipilimumab
- Arms
- SVV-001 Single Dose Treatment Group · Experimental
- SVV-001 Multi-Dose Treatment Group · Experimental
- SVV-001 RP2D Treatment Group · Experimental
- Enrollment
- 36 (estimated)
- Primary outcomes
- Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose
- Number of Participants Experiencing Dose Limiting Toxicities (DLTs): Part 1 Only
- Number of Participants Experiencing Treatment-Related Serious Adverse Events (SAEs)
- Number of Participants Experiencing Treatment-Related Adverse Events (AEs)
- Sponsor
- Peter Hosein, MD with Seneca Therapeutics
- Start
- May 19, 2025
- Primary completion
- Jun 1, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06889493 · updated Apr 28, 2026